These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 2875484

  • 1. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM, Darke C, Lazarus JH, Hall R, McGregor AM.
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [Abstract] [Full Text] [Related]

  • 2. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, Kendall-Taylor P.
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [Abstract] [Full Text] [Related]

  • 3. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A.
    N Engl J Med; 1996 Jan 25; 334(4):220-4. PubMed ID: 8531998
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan 25; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse.
    Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM.
    Q J Med; 1994 Jun 25; 87(6):337-41. PubMed ID: 7913766
    [Abstract] [Full Text] [Related]

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM, Shawkat W.
    Nucl Med Commun; 2008 Jul 25; 29(7):642-8. PubMed ID: 18528187
    [Abstract] [Full Text] [Related]

  • 7. A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.
    Allannic H, Fauchet R, Lorcy Y, Gueguen M, Le Guerrier AM, Genetet B.
    J Clin Endocrinol Metab; 1983 Oct 25; 57(4):719-22. PubMed ID: 6688428
    [Abstract] [Full Text] [Related]

  • 8. Remission with carbimazole therapy & assessment of T4 suppression test as an index of relapse in patients with Graves' disease in India.
    Goswami R, Bal CS, Gupta N, Kochupillai N.
    Indian J Med Res; 1996 May 25; 103():272-7. PubMed ID: 8707364
    [Abstract] [Full Text] [Related]

  • 9. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R.
    Horm Metab Res; 2002 Jul 25; 34(7):383-8. PubMed ID: 12189586
    [Abstract] [Full Text] [Related]

  • 10. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.
    Horm Metab Res; 2005 Dec 25; 37(12):741-4. PubMed ID: 16372227
    [Abstract] [Full Text] [Related]

  • 11. Once daily, low dose, short term antithyroid drug treatment of Graves' disease is followed by an unacceptably high relapse rate.
    Ford HC, Feek CM, Delahunt JW.
    N Z Med J; 1991 Mar 13; 104(907):97-8. PubMed ID: 2006072
    [Abstract] [Full Text] [Related]

  • 12. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
    Bliddal H, Bech K, Kirkegaard C.
    Horm Metab Res; 1984 Nov 13; 16(11):602-5. PubMed ID: 6210237
    [Abstract] [Full Text] [Related]

  • 13. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J, Gao H, Xu L.
    Zhonghua Yi Xue Za Zhi; 1994 Apr 13; 74(4):218-20, 254-5. PubMed ID: 7922762
    [Abstract] [Full Text] [Related]

  • 14. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM, Allannic H, Genetet N, Gueguen M, Genetet G, Fauchet R, Stefanutti A, Orgiazzi J.
    J Clin Endocrinol Metab; 1986 Jan 13; 62(1):117-21. PubMed ID: 3484386
    [Abstract] [Full Text] [Related]

  • 15. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M, Hussain M, Cundy T, Vergani D.
    J Clin Lab Immunol; 1989 Sep 13; 30(1):1-5. PubMed ID: 2577115
    [Abstract] [Full Text] [Related]

  • 16. The relationship of HLA-DR3 and outcome after antithyroid drugs to the IgG subclass distribution of thyroid autoantibodies in Graves' disease.
    Weetman AP, Cohen SB.
    Acta Endocrinol (Copenh); 1987 Feb 13; 114(2):292-7. PubMed ID: 3493611
    [Abstract] [Full Text] [Related]

  • 17. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
    Sanyal D, Mukhhopadhyay P, Pandit K, Chatterjee J, Raychaudhuri M, Mukherjee S, Chowdhury S.
    J Indian Med Assoc; 2008 Jun 13; 106(6):360-1, 372. PubMed ID: 18839646
    [Abstract] [Full Text] [Related]

  • 18. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT, Guillén CE, Sartorio GC, Soto RJ.
    Medicina (B Aires); 1992 Jun 13; 52(3):207-12. PubMed ID: 1364158
    [Abstract] [Full Text] [Related]

  • 19. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.
    Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V.
    J Clin Endocrinol Metab; 1990 Mar 13; 70(3):675-9. PubMed ID: 1689737
    [Abstract] [Full Text] [Related]

  • 20. Thyroid xenografts from patients with Graves' disease in severe combined immunodeficient mice and NIH-beige-nude-xid mice.
    Mukuta T, Arreaza G, Nishikawa M, Resetkova E, Jamieson C, Tamai H, Volpé R.
    Clin Invest Med; 1997 Feb 13; 20(1):5-15. PubMed ID: 9013039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.